Use of Tafenoquine to Treat a Patient With Relapsing Babesiosis With Clinical and Molecular Evidence of Resistance to Azithromycin and Atovaquone

Authors

Luis A. Marcos, Department of Medicine (Division of Infectious Diseases) and Department of Microbiology and Immunology, Stony Brook University, USA.
Annie Leung, Department of Medicine (Division of Infectious Diseases) and Department of Microbiology and Immunology, Weill Cornell Medical College, New York, NY, USA.
Laura Kirkman, Department of Medicine (Division of Infectious Diseases) and Department of Microbiology and Immunology, Weill Cornell Medical College, New York, NY, USA.
Gary P. Wormser, Division of Infectious Diseases, New York Medical College, Valhalla, NY, USA.Follow

Author Type(s)

Faculty

DOI

10.1016/j.idcr.2022.e01460

Journal Title

Idcases

First Page

e01460

Document Type

Article

Publication Date

1-1-2022

Department

Medicine

Keywords

Antibiotic resistance, Babesia microti, Babesiosis, Rituximab, Tafenoquine

Disciplines

Medicine and Health Sciences

Abstract

Tafenoquine is a highly effective treatment for infections in animal models. An immunocompromised patient infected by a strain of that was at least partially resistant to both azithromycin and atovaquone was treated with tafenoquine. Systematic clinical studies using tafenoquine for treating other patients with babesiosis should be considered.

Recommended Citation

Marcos, L. A., Leung, A., Kirkman, L., & Wormser, G. P. (2022). Use of Tafenoquine to Treat a Patient With Relapsing Babesiosis With Clinical and Molecular Evidence of Resistance to Azithromycin and Atovaquone. Idcases, 27, e01460. https://doi.org/10.1016/j.idcr.2022.e01460